National Psoriasis Foundation's statement on Genentech withdrawing Raptiva
The National Psoriasis Foundation recommends patients currently using Raptiva (efalizumab) to immediately contact their dermatologist and find an alternative treatment option. Patients should not stop using Raptiva without speaking with their physician—stopping abruptly could lead to a severe psoriasis flare.
The Psoriasis Foundation commends Genentech for their concern for patient safety.